Last updated on June 2009

Effect on Metabolic Parameters of Abilify in SPR


Brief description of study

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

Detailed Study Description

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Clinical Study Identifier: NCT00569764

Contact Investigators or Research Sites near you

Start Over

Jong-il Lee, M.D., Ph.D.

Seoul National Hospital
Seoul, Korea, Republic of
0.98miles
  Connect »